Acquisition - March 24, 2015
Skavak Buys Nordic Nanovector Shares
Skavak Invest AS, a company controlled by a close associate of Tone Kvåle, who is the chief financial officer of Nordic Nanovector ASA, purchased 3,000 shares in Nordic Nanovector ASA at an average share price of NOK 35 per share. Following the transaction and completion of the offering, Tone Kvåle will own 38,292 shares and […]
Acquisition - March 23, 2015
Deal for Genmab Holding, iDD
Genmab Holding B.V. a subsidiary of Genmab A/S, entered into an agreement to purchase antibodies and related patents from iDD Biotech SAS. The pre-clinical stage antibodies are directed to DR5, also known as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. Under the terms of the agreement, Genmab is expected to pay iDD Biotech EUR 2.5 […]
Acquisition - March 19, 2015
Recipharm, Adroit Form Partnership
Recipharm AB and Adroit Science AB have formed a strategic partnership. The companies plan to combine their expertise in formulation development, API development, chemical analysis and other areas to reduce time and cost of development while improving quality. “I very much look forward to cooperation,” says Carl-Johan Lever, executive vice president, development & technology at […]
Acquisition - March 12, 2015
Biotech to Sell Oral Cancer Test
Vigilant Biosciences, Inc., has entered into a three-year exclusive sales and marketing agreement with Biotech-IgG AB for the distribution of the OncAlert Oral Cancer Risk Assessment System in Denmark, Norway and Sweden. The OncAlert Oral Cancer Risk Assessment System includes a rapid, point-of-care risk assessment test (OncAlert POC Test) and a quantitative, laboratory test (OncAlert […]
Acquisition - March 12, 2015
AstraZeneca Buys More Respiratory Business
AstraZeneca recently acquired the rights to Actavis’ branded respiratory business in the US and Canada, according to a company announcement. As part of the agreement, AstraZeneca is paying Actavis $600 million of initial consideration and agreed to pay low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Actavis an additional $100 million for […]
Acquisition - March 5, 2015
Innokas Signs Two R&D Pacts
Innokas Medical has entered into R&D agreements with two healthcare technology companies operating in central Europe. Both agreements involve new customers for Innokas, and represent an important step in the company’s growth and internationalization. Under the first agreement, which was signed with a company headquartered in France, Innokas will develop a a patient monitoring device. […]
